Centocor initiates Ph II trial with MorphoSys' HuCAL-based Ab
Germany's MorphoSys says that its licensing partner, Centocor R&D of the USA, has enrolled a patient in a Phase II clinical trial with a HuCAL-derived fully-human antibody. A Phase I study using the same antibody in oncology patients was initiated in 2007 and is ongoing. The new trial is in an immunology indication. This achievement marks the first antibody, developed with MorphoSys' core technology, to enter human testing in a second indication with partners. The initiation of the Phase II trial and the Investigational New Drug in a new indication trigger (undisclosed) clinical milestone payments to MorphoSys.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze